Hematology / Oncology Salary
Hematology and oncology is financially strong but structurally in flux. Infusion suite economics and drug-margin policy shape the practice ceiling as much as visit volume does.
Median total cash compensation for a mid-career attending. Source: Doximity 2024 (publicly cited). Treat figures as medians, not targets. Real compensation varies widely by geography, employment model, and experience.
Live anonymous cohort, Hematology / Oncology
We display a live Hematology / Oncology cohort once at least 10 attendings have submitted in the last 24 months. Until then, the published benchmark and regional table below are your reference. Be one of the first to seed it.
Submit your comp anonymouslyHematology / Oncology pay by region
Directional regional medians, anchored to the Doximity 2024 national figure and US Census region adjustments. The South and Midwest pay more in absolute dollars because physician supply is lower and demand is higher; the Northeast runs lower with a higher cost of living.
| Region | Median total comp | Notes |
|---|---|---|
| National median | $445,000 | Doximity 2024 / Medscape 2024 nationwide median. |
| South | $489,500 | Highest absolute compensation. Houston, Jacksonville, Charlotte, Atlanta lead. |
| Midwest | $480,600 | Indianapolis and St. Louis often top Doximity median tables. |
| West | $453,900 | Wide spread. California pays well but is offset by cost of living. |
| Northeast | $431,650 | Lower in absolute terms (high supply of physicians) and higher cost of living. |
Regional figures are modeled adjustments to the national median, not separately surveyed values. Use them for direction, not as an offer benchmark.
What drives Hematology / Oncology compensation
- Infusion suite volume and the economics of in-office drug administration.
- Drug-margin and site-of-service policy, which is actively shifting and affects practice income.
- Complex visit and care-management capture across a high-acuity panel.
- Employed cancer center versus private group structure, which determines exposure to drug economics.
Model your own number, not the median
Hematology / Oncology reports a median of about 7,800 wRVUs a year. Your take-home is that volume times your contract rate, above your threshold. Plug your real visit mix into the calculator and see the bonus your specific offer produces, then negotiate against it.
Negotiation levers at offer time
- •Understand how the practice handles drug margin, since policy changes can swing private group income materially.
- •Confirm complex E/M and care-management crediting given the acuity of an oncology panel.
- •Weigh the stability of an employed cancer center against the upside and risk of a private group.
Hematology / Oncology at a glance
Emotionally heavy but financially strong. Drug-margin economics shifting. Typical setting: infusion clinic + inpatient consults.
Frequently asked questions
What drives hematology and oncology compensation?
Infusion economics and visit complexity. In-office drug administration and a high-acuity panel carry income, while drug-margin policy increasingly shapes the private practice ceiling.
Why is oncology drug margin a compensation issue?
In private group settings, in-office infusion margin has historically been a meaningful income component, and active site-of-service policy changes can move group economics in either direction.
Employed cancer center or private oncology group?
Employed roles smooth out drug-economics risk and are more predictable. Private groups retain more upside but carry policy exposure that should be modeled before signing.
Filter every specialty by region with the live cohort tool.
Anonymous, 90 seconds. NPI verification weights your data 3x.
The codes that actually drive this specialty's wRVUs.
30-year cumulative earnings with regional cost adjustment.
Educational reference, not financial, billing, or legal advice. Published medians are publicly cited from Doximity 2024. The live cohort is self-reported and anonymized; individual rows are never exposed and a cohort is shown only at a minimum size. Verify any number against your own contract and market before acting on it.